Emerging Inflammatory Bowel Disease Treatment Market Trends: Verantos Launches AI-Driven Inflammatory Bowel Disease Pragmatic Registry to Enhance Treatment Research Shaping the Future of the Industry

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Inflammatory Bowel Disease Treatment Market Size Growth Forecast: What to Expect by 2025?
The market for inflammatory bowel disease treatment has seen significant progress over the past few years. The market, which was valued at $25.26 billion in 2024, is projected to rise to $27.45 billion in 2025, growing at a compound annual growth rate (CAGR) of 8.6%. Several factors have contributed to this growth in the historic period such as the surge in cases of inflammatory bowel disease, the escalating need for biologics and immunomodulators, advancements in therapeutic alternatives, the increase in the elderly population, as well as heightened disease awareness.

How Will the Inflammatory Bowel Disease Treatment Market Size Evolve and Grow by 2029?
The market size for the treatment of inflammatory bowel disease is anticipated to experience swift expansion in the upcoming years. The estimation is that it will escalate to $40.27 billion in 2029, with a 10.1% compound annual growth rate (CAGR). Factors contributing to this growth during the prediction period range from escalated investment in research and development activities, an increased requirement for biosimilars, a surge in the number of inflammatory bowel disease instances in developing markets, a growing need for individualized medicine to the integration of precision medicine in IBD treatment. Key trends expected during this forecast period include the rise in product launches and approvals, customizable dosing and treatment regimes in IBD management, application of telemedicine for distant monitoring of IBD patients, investigation into microbiome-based therapies for IBD, and the incorporation of value-based care models in IBD treatment.

View the full report here:
https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

What Drivers Are Propelling the Growth of Inflammatory Bowel Disease Treatment Market Forward?
The escalating incidence of Crohn's disease and ulcerative colitis is a major catalyst for the growth of the inflammatory bowel disease treatment market. Both Crohn's disease and ulcerative colitis are forms of inflammatory bowel diseases, known for causing inflammation and sores in the digestive system. The surge in these disorders is anticipated to stimulate the demand for inflammatory bowel disease therapies as they are predominantly used to minimize bowel inflammation and avert potential medical issues. For example, research published in the United States National Library of Medicine in March 2022, indicates that approximately 1.6 million Americans are currently living with inflammatory bowel disease (Crohn's disease or ulcerative colitis), and nearly 70,000 fresh cases of IBD are identified annually in the USA. Thus, the increasing prevalence of Crohn's disease and ulceric colitis is predicted to propel the growth of the inflammatory bowel disease treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

Which Emerging Trends Are Transforming the Inflammatory Bowel Disease Treatment Market in 2025?
Rapid technological advances are becoming a predominant trend in the inflammatory bowel disease treatment market. Many leading companies in the market are utilizing AI-powered registries to gain a competitive advantage. For example, in May 2024, Verantos, a California-based company that specializes in real-world evidence (RWE), introduced the Inflammatory Bowel Disease Pragmatic Registry. This system, which uses cutting-edge artificial intelligence, generates high-quality real-world evidence (RWE) for both ulcerative colitis and Crohn's disease. The purpose of the registry is to hasten the creation of effective therapies by providing a comprehensive dataset containing over 3 billion data points related to patient care. This allows biopharma researchers to get detailed insights into numerous aspects, like the severity of the disease, the efficacy of treatment, and clinical outcomes, by leveraging both structured and unstructured data from electronic health records.

What Are the Key Segments in the Inflammatory Bowel Disease Treatment Market?
The inflammatory bowel disease treatment market covered in this report is segmented -

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn's Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=6704&type=smp

Who Are the Key Players Shaping the Inflammatory Bowel Disease Treatment Market's Competitive Landscape?
Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic - Gastroenterology West P. C., Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.

What Geographic Markets Are Powering Growth in the Inflammatory Bowel Disease Treatment Market?
North America was the largest region in the inflammatory bowel disease treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6704

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.